Beijing-based QL Biopharmaceutical announced that its once-monthly GLP-1 receptor agonist, zovaglutide (ZT-002), achieved primary and secondary efficacy endpoints in a randomized phase II trial targeting obesity. The study enrolled overweight and obese patients, demonstrating significant weight reductions across dosing regimens compared to placebo. These positive results support advancement to pivotal phase III studies. The development aligns with growing interest in monthly GLP-1 treatments for metabolic disorders.